Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Hepatocellular Carcinoma · Obesity

Hospital Authority

Hospital Authority, Hong Kong

Hospital Authority clinical programs — 322 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website
Hospital Authority Building, 147B Argyle Street, Kowloon, Hong Kong, 852, HK, CN HQ
1991 Founded
12,669 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Hospital Authority Building, 147B Argyle Street, Kowloon, Hong Kong, 852, HK, CN
Founded
1991
Employees
12,669
Programs
322
Drugs
301
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

Hospital Authority projects

322 ClinicalTrials.gov programs sponsored by Hospital Authority.

Hospital Authority has 322 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

322 programs

Clinical programs

Page 4 of 7

  1. CAR T-cell therapy

    Hospital Authority, Hong Kong

    Lymphoblastic Leukemia, Acute, Childhood

    phase 1 mab active

    1 trial

  2. Cordyceps cicadae extract

    Hospital Authority, Hong Kong

    Myopia

    phase 1 mab completed

    1 trial

  3. Digoxin

    Hospital Authority, Hong Kong

    Healthy

    phase 1 small molecule completed

    1 trial

  4. Drugs administration

    Hospital Authority, Hong Kong

    Rotator Cuff Tears of the Shoulder

    phase 1 small molecule active

    1 trial

  5. Extraluminal use of Univent bronchial Blocker

    Hospital Authority, Hong Kong

    Therapeutic Procedural Complication

    phase 1 other completed

    1 trial

  6. Fospropofol disodium

    Hospital Authority, Hong Kong

    Drug Safety

    phase 1 small molecule completed

    1 trial

  7. HBV mRNA vaccine

    Hospital Authority, Hong Kong

    Hepatocellular Carcinoma (HCC)

    phase 1 mab active

    1 trial

  8. INAVAC (Vaksin Merah Putih - UA- SARS CoV-2 (Vero Cell Inactivated) 5 μg

    Hospital Authority, Hong Kong

    COVID-19 Pandemic

    phase 1 mab active

    1 trial

  9. Implantation

    Hospital Authority, Hong Kong

    Bone Loss

    phase 1 other active

    1 trial

  10. Intercerebral implantation of allogenic CD34+ stem cell

    Hospital Authority, Hong Kong

    Ischemic Stroke

    phase 1 other active

    1 trial

  11. Interleukin, NK cells

    Hospital Authority, Hong Kong

    Metastatic Nasopharyngeal

    phase 1 small molecule completed

    1 trial

  12. Larotrectinib

    Hospital Authority, Hong Kong

    High Grade Glioma

    phase 1 small molecule active

    1 trial

  13. MTL-CEBPA

    Hospital Authority, Hong Kong

    Advanced Hepatocellular Carcinoma

    phase 1 small molecule active

    1 trial

  14. Motion analysis of patients

    Hospital Authority, Hong Kong

    Leg Length Discrepancy

    phase 1 other completed

    1 trial

  15. Neoadjuvant chemotherapy

    Hospital Authority, Hong Kong

    Squamous Cell Carcinoma of Oral Cavity

    phase 1 small molecule completed

    1 trial

  16. OPB-51602

    Hospital Authority, Hong Kong

    Nasopharyngeal Carcinoma

    phase 1 small molecule terminated

    1 trial

  17. Oxidized regenerated cellulose(ORC)

    Hospital Authority, Hong Kong

    Thyroidectomy

    phase 1 small molecule completed

    1 trial

  18. PRG-1801

    Hospital Authority, Hong Kong

    Immune Thrombocytopenia

    phase 1 small molecule active

    1 trial

  19. Paclitaxel

    Hospital Authority, Hong Kong

    Ovarian Cancer

    phase 1 small molecule active

    1 trial

  20. SNUCPT08_GCPGC

    Hospital Authority, Hong Kong

    Healthy

    phase 1 small molecule completed

    1 trial

  21. Silodosin

    Hospital Authority, Hong Kong

    Benign Prostatic Hyperplasia

    phase 1 small molecule completed

    1 trial

  22. Tissue Plasminogen Activator (tPA)

    Hospital Authority, Hong Kong

    Peritoneal Dialysis

    phase 1 small molecule terminated

    1 trial

  23. UTAA91 injection

    Hospital Authority, Hong Kong

    Rheumatoid Arthritis (RA)

    phase 1 mab active

    1 trial

  24. Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) 5 µg

    Hospital Authority, Hong Kong

    COVID-19 Pandemic

    phase 1 mab active

    1 trial

  25. 201010025M

    Hospital Authority, Hong Kong

    Hepatitis

    approved small molecule active

    1 trial

  26. 3 % Minoxidil lotion

    Hospital Authority, Hong Kong

    Beard Enhancement

    approved small molecule completed

    1 trial

  27. 6-month clopidogrel therapy

    Hospital Authority, Hong Kong

    Coronary Artery Disease

    approved small molecule completed

    1 trial

  28. Alendronate

    Hospital Authority, Hong Kong

    Non-Traumatic Osteonecrosis

    approved small molecule active

    1 trial

  29. Allopurinol Tablet 300 mg

    Hospital Authority, Hong Kong

    Kidney Calculi

    approved small molecule completed

    1 trial

  30. Aripiprazole

    Hospital Authority, Hong Kong

    First Episode Psychosis

    approved small molecule completed

    1 trial

  31. Bismuth-based susceptibility-guided treatment

    Hospital Authority, Hong Kong

    Helicobacter Pylori

    approved small molecule completed

    1 trial

  32. Breeze2 glucometer

    Hospital Authority, Hong Kong

    Diabetes

    approved other active

    1 trial

  33. Bupivacaine

    Hospital Authority, Hong Kong

    Pain

    approved small molecule completed

    1 trial

  34. Byfavo

    Hospital Authority, Hong Kong

    Bronchoscopy

    approved small molecule completed

    1 trial

  35. Chlorhexidine gluconate

    Hospital Authority, Hong Kong

    Liver Tumors

    approved small molecule completed

    1 trial

  36. Combination Cinacalcet with Vitamin D analogue

    Hospital Authority, Hong Kong

    Secondary Hyperparathyroidism

    approved small molecule active

    1 trial

  37. Continuos epidural infusion

    Hospital Authority, Hong Kong

    Analgesia, Epidural

    approved other active

    1 trial

  38. Cook balloon uterine stent

    Hospital Authority, Hong Kong

    Intrauterine Adhesion

    approved other completed

    1 trial

  39. Dexamethasone and N-acetylcysteine (NAC)

    Hospital Authority, Hong Kong

    Carbon Monoxide Poisoning

    approved small molecule active

    1 trial

  40. Dexmedetomidine

    Hospital Authority, Hong Kong

    Thyroid Diseases

    approved small molecule active

    1 trial

  41. Dextrose 5%

    Hospital Authority, Hong Kong

    End-Stage Kidney Disease

    approved small molecule active

    1 trial

  42. Etomidate

    Hospital Authority, Hong Kong

    Choledocholithiasis

    approved small molecule completed

    1 trial

  43. Finerenone

    Hospital Authority, Hong Kong

    Heart Failure and Preserved Ejection Fraction

    approved small molecule active

    1 trial

  44. Forsteo

    Hospital Authority, Hong Kong

    Spine Deformity

    approved small molecule active

    1 trial

  45. Group C : Saline + propofol group

    Hospital Authority, Hong Kong

    Urologic Surgery

    approved small molecule completed

    1 trial

  46. Intraosseous

    Hospital Authority, Hong Kong

    Cardiac Arrest

    approved other completed

    1 trial

  47. Intraosseous Morphine

    Hospital Authority, Hong Kong

    Pain Postoperative

    approved other active

    1 trial

  48. Ixekizumab

    Hospital Authority, Hong Kong

    Plaque Psoriasis

    approved mab active

    1 trial

Frequently asked questions

How many clinical projects does Hospital Authority have?

322 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.